Coronado Biosciences Announces the Pricing of Public Offering of Common Stock

BURLINGTON, Mass., June 22, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $5.00 per share for gross proceeds to Coronado of $25.0 million. Coronado expects to receive approximately $23.0 million in net proceeds from the offering, after deducting underwriting discount and estimated offering expenses. The Company also has granted the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over-allotments, if any. The offering is expected to close on June 27, 2012, subject to customary closing conditions.